dlx105
mAbexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00819572)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- dlx105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04203433 | Phase 1/Phase 2 (Phase 2) | Feb 29, 2020 | Arrivo Bioventures |
| NCT01936337 | Phase 2 | Aug 1, 2013 | Delenex Therapeutics AG |
| NCT01624376 | Phase 2 | Jun 1, 2012 | Delenex Therapeutics AG |
| NCT01595997 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2012 | Delenex Therapeutics AG |
| NCT00819572 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2008 | ESBATech AG, University of Erlangen-Nuremberg, University of Zurich |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Delenex Therapeutics AG | For profit | 3 | 3 | 1 | 2012 |
| Arrivo Bioventures | For profit | 1 | 1 | 1 | 2020 |
| ESBATech AG | For profit | 1 | 1 | 1 | 2008 |
| University of Erlangen-Nuremberg | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1